Hatchtech Pty Ltd is an innovative biotechnology company developing novel solutions for everyday health problems based in Melbourne, Australia. Its lead development product, Xeglyze™, is a single dose, single treatment, topical prescription product for the control of head lice and was approved by the FDA in July 2020.
Looking for a particular Hatchtech Pty Ltd employee's phone or email?
The Hatchtech Pty Ltd annual revenue was $7 million in 2026.
Hatchtech Pty Ltd is based in Camberwell, Victoria.
The NAICS codes for Hatchtech Pty Ltd are [32541, 3254, 32, 325].
The SIC codes for Hatchtech Pty Ltd are [283, 28].